4 recruiting, 3 completed, 3 not yet recruiting. 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Recruiting 4, Completed 3, Not yet recruiting 3 |
Follow Hunan Kelun Pharmaceutical Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults KL0011034 Injection, Propofol Injectable Emulsion - Healthy Participants Study, General Anesthesia | Phase 1 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 30 | 2026-11-06 | 2026-09-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects KL0011034 injection, propofol injectable emulsion - Healthy Volunteers | Phase 1 | Not yet recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | 30 | 2026-10-13 | 2026-09-18 |
| A Study to Evaluate the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection in Participants With Moderate-to-Severe Non-Cancer Chronic Pain KL0011034 injection, Alfentanil Hydrochloride Injection - Chronic Pain | Phase 1 | Not yet recruiting | The Third Xiangya Hospital of Central South University | 27 | 2026-07-30 | 2026-08-07 |
| A Study Evaluating the Drug-Drug Interaction Between KL0011034 Injection and Alfentanil Hydrochloride Injection KL0011034 injection, Alfentanil Hydrochloride Injection - Chronic Pain | Phase 1 | Completed | Hunan Kelun Pharmaceutical Co., Ltd. | 27 | 2026-07-15 | 2026-09-17 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KL0011034 Injection in Healthy Volunteers KL0011034 injection, Placebo, Etomidate Injectable Emulsion - Healthy Volunteers | Phase 1 | Recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | 76 | 2026-03-02 | 2026-05-27 |
| Single-dose,First-in-human of KLA478 pramipexole hydrochloride sustained-release tablets, KLA478, placebo - Healthy Volunteers | Phase 1 | Recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | 40 | 2025-11-26 | 2026-05-26 |
| A Phase I Study of KLA318-2 Nanocrystal Injection KLA318-2 Nanocrystal Injection, Celebrex Capsule - Healthy Participants | Phase 1 | Recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | 48 | 2025-09-01 | 2026-05-26 |
| First-in-Human Single and Multiple Dose of KLA578-1 for Injection KLA578-1 for injection, Etopcoxib Tablets - Healthy Volunteers | Phase 1 | Recruiting | Hunan Kelun Pharmaceutical Co., Ltd. | 48 | 2025-06-05 | 2026-05-26 |
| Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions Gefitinib Tablet 250mg of Hunan Kelun, Iressa® Tablet 250mg of AZN - Bioequivalence Study | Phase 1 | Completed | Hunan Kelun Pharmaceutical Co., Ltd. | 38 | 2016-09-08 | 2026-05-26 |
| Bioequivalence Study of Gefitinib Tablets Under Fed Conditions Gefitinib Tablet 250mg of Hunan Kelun, Iressa® Tablet 250mg of AZN - Healthy | Phase 1 | Completed | Hunan Kelun Pharmaceutical Co., Ltd. | 38 | 2016-09-01 | 2026-05-26 |
Chronic Pain (2)
Alfentanil (2) · Gefitinib (2) · Celecoxib (1) · Injections (1)
China (6)